European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024
European Journal of Cancer,
Год журнала:
2024,
Номер
215, С. 115153 - 115153
Опубликована: Ноя. 29, 2024
Язык: Английский
The Dutch Early-Stage Melanoma (D-ESMEL) study: a discovery set and validation cohort to predict the absolute risk of distant metastases in stage I/II cutaneous melanoma
European Journal of Epidemiology,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 9, 2025
Abstract
Early-stage
cutaneous
melanoma
patients
generally
have
a
favorable
prognosis,
yet
significant
proportion
of
metastatic
cases
arise
from
this
group,
highlighting
the
need
for
improved
risk
stratification
using
novel
prognostic
biomarkers.
The
Dutch
Early-Stage
Melanoma
(D-ESMEL)
study
introduces
robust,
population-based
methodology
to
develop
an
absolute
prediction
model
stage
I/II
melanoma,
incorporating
clinical,
imaging,
and
multi-omics
data
identify
at
increased
distant
metastases.
Utilizing
Netherlands
Cancer
Registry
Nationwide
Pathology
Databank,
we
collected
primary
tumor
samples
early-stage
patients,
with
without
metastases
during
follow-up.
Our
design
includes
discovery
set
matched
controls
factors,
followed
by
validation
cohort
nested
case–control
validate
these
factors
build
model.
Tissue
sections
underwent
Hematoxylin
&
Eosin
(H&E)
staining,
RNA
sequencing
(RNAseq),
DNA
(DNAseq),
immunohistochemistry
(IHC),
multiplex
immunofluorescence
(MxIF).The
included
442
(221
sets),
46%
I
54%
II
melanomas.
median
time
metastasis
was
3.4
years,
while
had
follow-up
9.8
years.
154
random
selection
5,815
patients.
approach
enabled
collection
large
number
databases
extensive
sufficient
events.
This
in
cancer
research
holds
potential
impact
clinical
decision-making
through
prediction.
Язык: Английский
Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial
Annals of Surgical Oncology,
Год журнала:
2025,
Номер
32(4), С. 2756 - 2764
Опубликована: Фев. 1, 2025
Язык: Английский
Adjuvant Anti–PD-1 Monotherapy Versus Observation for Stage III Acral Melanoma of the Sole: A Multicenter Retrospective Study in Japanese Patients
JCO Global Oncology,
Год журнала:
2025,
Номер
11
Опубликована: Апрель 1, 2025
PURPOSE
Adjuvant
anti–PD-1
(adj
PD-1)
antibodies
are
extensively
used
to
improve
survival
in
patients
with
resected
melanoma.
Clinical
trials
on
adj
PD-1
have
revealed
significant
improvements
recurrence-free
(RFS);
however,
few
of
these
included
acral
melanoma
(AM).
METHODS
data
were
retrospectively
collected
from
Japanese
who
underwent
resection
stage
III
sole
AM
between
2014
and
2021.
Survival
outcomes,
including
RFS,
distant
metastasis-free
(DMFS),
overall
(OS),
compared
without
adjuvant
therapy
(OBS
group)
those
receiving
group.
RESULTS
This
study
139
(OBS:
79;
PD-1:
60),
a
median
follow-up
2.6
years.
The
baseline
characteristics
comparable,
except
for
age
nodal
metastasis.
No
differences
observed
the
OBS
groups
(3-year
RFS:
36.7%
v
27.5%,
P
=
.13;
3-year
DMFS:
51.0%
45.3%,
.51;
OS:
65.3%
67.4%,
.45).
Multivariate
analysis
showed
no
benefit
(RFS:
hazard
ratio
[HR],
1.25,
.29;
HR,
1.03,
.89;
0.69,
.23).
Each
outcome
after
propensity
score
matching
confirmed
difference
matched
group
(n
52)
52;
34.3%
25.9%,
.22;
45.6%
46.5%,
.85;
60.7%
68.9%,
.29).
CONCLUSION
Adj
did
not
prognosis
AM.
However,
further
studies
essential
evaluate
efficacy
antibody
Язык: Английский
Recent Advances of Neoadjuvant Immunotherapy for Urothelial Bladder Cancer
Annals of Surgical Oncology,
Год журнала:
2024,
Номер
unknown
Опубликована: Июль 12, 2024
Язык: Английский
Advances in predictive biomarkers for melanoma immunotherapy
Holistic Integrative Oncology,
Год журнала:
2024,
Номер
3(1)
Опубликована: Окт. 11, 2024
Abstract
Purpose
This
review
primarily
discusses
the
current
research
advance
of
predictive
biomarkers
for
melanoma
immunotherapy.
The
aim
present
is
to
summarize
and
evaluate
advantages
disadvantages.
Methods
All
reference
can
be
found
through
Pubmed.
mainly
focuses
on
three
main
directions:
tumor-related
factors,
host
tumor
microenvironment.
In
end,
there
exhibits
some
unusual
aspects
forecasts
future
model.
Results
mainsteam
PD-L1,
TMB,
gene
mutations,
immune
cells,
IDO1,
LDH,
tertiary
lymphoid
structures
(TLS),
HLA-DR,
tumor-associated
macrophages
(TAMs),
tumor-infiltrating
lymphocytes
(TILs),
Extracellular
vesicles
(EVs).
Conclusion
immunotherapy
divided
into
parts:
include
TLS,
TAMs,
TILs,
EVs.
A
model
based
multiple
expected
become
answer
predicting
prognosis.
Язык: Английский